The Lancet. Child & adolescent health
Weight gain, body composition, and metabolic parameters of dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: an ancillary analysis of the ODYSSEY trial.
Anna Turkova, Ellen White, Avy Violari, Hilda A Mujuru, Adeodata R Kekitiinwa, Abbas Lugemwa, Elizabeth Kaudha, Sathaporn Na-Rajsima, Grace M Ahimbisibwe, Ebrahim Variavae, Moherndran Archary, Yasmeen Akhalwaya, Thanyawee Puthanakit, Mutsa Bwakura-Dangarembizi, Dickson Bbuye
Published: 202610.1016/S2352-4642(25)00339-6
Abstract
BACKGROUND: ODYSSEY trial showed superior efficacy of dolutegravir-based antiretroviral therapy (ART) versus then-current, non-dolutegravir standard of care over 96 weeks in children and adolescents living with HIV. The aim of this ancillary analysis…
Preview only. Read the full abstract at the source